Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On November 7, 2022, we reviewed a study published in Neurology that examined the association between cumulative alcohol burden and the risk for stroke among young adults.
The study
Researchers tapped the Korean National Health Insurance Service database for participants, seeking adults ages 20 to 29 years who had 4 consecutive annual health exams from 2009 to 2012. Based on participants’ (n=1 536 668) self-report of alcohol consumption at the exams, the investigators calculated a cumulative alcohol burden score for each by assigning a score of 1 for each year weekly alcohol consumption was reported at ≥105 g. Burden scores ranged from 0 (no years at that level of alcohol consumption) to 4 (4 years with weekly alcohol consumption at ≥105 g). People who drank 105 g of alcohol per week, or 15 g per day, for 2 years were 19% more likely to have a stroke over approximately 6 years of study follow-up vs light drinkers.
Clinical implications
"Reducing alcohol consumption should be emphasized in young adults with heavy drinking habits as part of any stroke prevention strategy," wrote authors.
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.